A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design.
Jingran Ji, Catherine M Crespi, Lisa Yee...
https://pubmed.ncbi.nlm.nih.gov/41835341/Actively Recruiting
Led by Jonsson Comprehensive Cancer Center · Updated on 2026-07-17
88
Participants Needed
7
Research Sites
52 weeks
Total Duration
Researchers are evaluating the effect of fisetin, a natural substance found in strawberries and other foods, on physical function in postmenopausal women who have received chemotherapy for stage I-III breast cancer. This phase II trial focuses on whether fisetin can help improve physical function by eliminating senescent cells that accumulate after chemotherapy, which may cause inflammation and damage to healthy cells. Participants are randomly assigned to receive either fisetin or a placebo orally on days 1, 2, and 3, repeated every two weeks for up to eight weeks, unless disease progression or unacceptable side effects occur. Blood samples are collected throughout the trial to study various biological markers. After treatment, participants are followed yearly for up to three years to monitor long-term outcomes. During the study, participants undergo assessments of physical function such as the 6-minute walk distance, grip strength, and frailty measures. Researchers also evaluate fatigue, neuropathy, cognitive function, quality of life, sleep, anxiety, and depression. Safety and adherence to the study treatment are monitored through patient reports and diaries. The study tracks recurrence-free survival and overall survival over three years, aiming to better understand how fisetin affects health after chemotherapy.
CONDITIONS
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
M
Mina S. Sedrak, MD
K
Kelly Synold
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Jonsson Comprehensive Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Fisetin | Placebo |
|---|---|---|
| What this approach is | An investigational oral senolytic (fisetin) given for four 14‑day cycles (days 1–3) | A matching oral placebo given on the same schedule over four 14‑day cycles |
| Role in the trial | Participants are randomized to receive the investigational senolytic fisetin | Participants are randomized to receive placebo as control |
| Primary focus | Test whether fisetin improves physical function (6‑minute walk distance from baseline to end of treatment) | Baseline comparator for assessing change in physical function over same period |
| Administration schedule | Orally on days 1–3 of each 14‑day cycle for four cycles | Orally on days 1–3 of each 14‑day cycle for four cycles, matching fisetin |
| Evidence maturity | Clinical benefit under investigation; this is a phase II study without published efficacy results yet | Placebo control; not a current standard therapy for post‑chemotherapy frailty |
| Key limitations | Phase II trial targeting functional decline; not designed to evaluate long‑term survival or disease outcomes | Placebo does not reflect real‑world supportive care or rehabilitative interventions |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Up to 8 weeks
Participants receive fisetin or a placebo orally on days 1, 2, and 3 every two weeks for up to eight weeks, unless disease progression or unacceptable side effects occur. Blood samples are collected during this period.
Visits every 2 weeks for treatment dosing and assessments
Duration - Up to 3 years
Participants are followed yearly for up to three years to monitor physical function, cancer recurrence, survival, and overall health.
Annual follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jingran Ji, Catherine M Crespi, Lisa Yee...
https://pubmed.ncbi.nlm.nih.gov/41835341/Jonsson Comprehensive Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor